Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
105.4 USD | -0.73% | -1.36% | -4.75% |
04-29 | Abbott's Dissolving Stent Gets FDA Approval For Arteries Below the Knee | MT |
04-26 | Dexcom's profit beats estimates on strong glucose monitor demand | RE |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.75% | 185B | |
-0.79% | 109B | |
-3.93% | 68.54B | |
+2.84% | 51.74B | |
+9.00% | 45.22B | |
+3.12% | 41.74B | |
+4.13% | 26.83B | |
+3.18% | 26.69B | |
+11.62% | 25.63B | |
-0.68% | 24.98B |
- Stock Market
- Equities
- ABT Stock
- News Abbott Laboratories
- Abbott Laboratories : Raymond James Adjusts Price Target on Abbott Laboratories to $126 From $114, Keeps Outperform Rating